RS51056B - Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju psihotičkih poremećaja - Google Patents

Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju psihotičkih poremećaja

Info

Publication number
RS51056B
RS51056B YUP-675/03A YUP67503A RS51056B RS 51056 B RS51056 B RS 51056B YU P67503 A YUP67503 A YU P67503A RS 51056 B RS51056 B RS 51056B
Authority
RS
Serbia
Prior art keywords
formula
group
phenyl
alkyl
psychotic disorders
Prior art date
Application number
YUP-675/03A
Other languages
English (en)
Serbian (sr)
Inventor
Carlos R. Plata-Salaman
Boyu Zhao
Roy E. Twyman
Original Assignee
Ortho-Mcneil Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical Inc. filed Critical Ortho-Mcneil Pharmaceutical Inc.
Publication of RS67503A publication Critical patent/RS67503A/sr
Publication of RS51056B publication Critical patent/RS51056B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
YUP-675/03A 2001-02-27 2002-02-21 Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju psihotičkih poremećaja RS51056B (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27188901P 2001-02-27 2001-02-27
PCT/US2002/006119 WO2002067927A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating psychotic disorders
US10/081,761 US6541513B2 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating psychotic disorders

Publications (2)

Publication Number Publication Date
RS67503A RS67503A (sr) 2006-12-15
RS51056B true RS51056B (sr) 2010-10-31

Family

ID=26765939

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-675/03A RS51056B (sr) 2001-02-27 2002-02-21 Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju psihotičkih poremećaja

Country Status (25)

Country Link
US (1) US6541513B2 (cg-RX-API-DMAC7.html)
EP (1) EP1401424B1 (cg-RX-API-DMAC7.html)
JP (1) JP4276841B2 (cg-RX-API-DMAC7.html)
KR (1) KR100886578B1 (cg-RX-API-DMAC7.html)
CN (1) CN1262271C (cg-RX-API-DMAC7.html)
AR (1) AR032876A1 (cg-RX-API-DMAC7.html)
AT (1) ATE346597T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002242296B2 (cg-RX-API-DMAC7.html)
BR (1) BR0207829A (cg-RX-API-DMAC7.html)
CA (1) CA2439480C (cg-RX-API-DMAC7.html)
CZ (1) CZ302412B6 (cg-RX-API-DMAC7.html)
DE (1) DE60216457T2 (cg-RX-API-DMAC7.html)
DK (1) DK1401424T3 (cg-RX-API-DMAC7.html)
ES (1) ES2275844T3 (cg-RX-API-DMAC7.html)
HU (1) HUP0303342A3 (cg-RX-API-DMAC7.html)
IL (2) IL157588A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03007722A (cg-RX-API-DMAC7.html)
NO (1) NO20033801L (cg-RX-API-DMAC7.html)
NZ (1) NZ527991A (cg-RX-API-DMAC7.html)
PL (1) PL365021A1 (cg-RX-API-DMAC7.html)
PT (1) PT1401424E (cg-RX-API-DMAC7.html)
RS (1) RS51056B (cg-RX-API-DMAC7.html)
RU (1) RU2302240C2 (cg-RX-API-DMAC7.html)
TW (1) TWI251486B (cg-RX-API-DMAC7.html)
WO (1) WO2002067927A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL365701A1 (en) * 2000-07-21 2005-01-10 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
WO2003007934A1 (en) 2001-07-16 2003-01-30 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
MXPA03007720A (es) 2001-02-27 2004-11-12 Johnson & Johnson Compuestos de carbamato para su uso en la prevencion o el tratamiento de transtornos de ansiedad.
DE60220043T2 (de) * 2001-02-27 2008-01-10 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
EP1744750A2 (en) * 2004-05-06 2007-01-24 Sandoz AG Pharmaceutical composition comprising hydrophobic drug having improved solubility
EP1928451B1 (en) * 2005-07-26 2011-12-28 SK Biopharmaceuticals Co., LTD Methods for treating substance-related disorders
CN101568362A (zh) * 2006-10-30 2009-10-28 詹森药业有限公司 治疗抑郁症的方法
JP2010508354A (ja) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 広汎性発達障害の処置
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
JP6062077B2 (ja) 2013-03-12 2017-01-18 バイオ−ファーム ソリューションズ カンパニー リミテッド 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物{phenylcarbamatecompoundsforuseinpreventingortreatingpediatricepilesyandepilesy−relatedsyndromes}
WO2014142547A1 (en) * 2013-03-12 2014-09-18 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compound and a composition for neuroprotection comprising the same
KR102900173B1 (ko) * 2016-12-14 2025-12-12 에스케이바이오팜 주식회사 조현병, 강박장애 및 투렛증후군으로부터 선택되는 정신증 장애의 예방, 경감 또는 치료에 있어서의 카바메이트 화합물의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US278380A (en) * 1883-05-29 Thermometer
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
EP0480939B1 (en) * 1989-06-09 1995-01-25 The Upjohn Company Heterocyclic amines having central nervous system activity
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol

Also Published As

Publication number Publication date
CZ302412B6 (cs) 2011-05-04
NO20033801D0 (no) 2003-08-26
CZ20032297A3 (cs) 2004-06-16
HUP0303342A3 (en) 2012-07-30
RS67503A (sr) 2006-12-15
DK1401424T3 (da) 2007-02-26
AU2002242296B2 (en) 2006-06-29
CN1505507A (zh) 2004-06-16
NZ527991A (en) 2005-04-29
JP2004523556A (ja) 2004-08-05
DE60216457D1 (de) 2007-01-11
RU2003128983A (ru) 2005-03-10
US20020165272A1 (en) 2002-11-07
WO2002067927A1 (en) 2002-09-06
MXPA03007722A (es) 2004-11-12
AR032876A1 (es) 2003-11-26
IL157588A0 (en) 2004-03-28
ES2275844T3 (es) 2007-06-16
KR100886578B1 (ko) 2009-03-05
PT1401424E (pt) 2007-02-28
RU2302240C2 (ru) 2007-07-10
ATE346597T1 (de) 2006-12-15
KR20030076713A (ko) 2003-09-26
HUP0303342A2 (hu) 2004-01-28
JP4276841B2 (ja) 2009-06-10
EP1401424B1 (en) 2006-11-29
EP1401424A1 (en) 2004-03-31
DE60216457T2 (de) 2007-09-20
TWI251486B (en) 2006-03-21
US6541513B2 (en) 2003-04-01
NO20033801L (no) 2003-10-22
CN1262271C (zh) 2006-07-05
CA2439480C (en) 2011-04-26
PL365021A1 (en) 2004-12-27
BR0207829A (pt) 2004-06-22
IL157588A (en) 2009-12-24
CA2439480A1 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
RU2338537C2 (ru) СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
CA3225008A1 (en) Safer psychoactive compositions
RS67503A (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju psihotičnih poremećaja
RS50676B (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
RS67403A (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neurodegenerativnih poremećaja
US9023788B2 (en) Methods compounds and pharmaceutical compositions for treating anxiety and mood disorders
HK1247847A1 (zh) 四氢-N,N-二甲基-2,2-二苯基-3-呋喃甲胺的对映体(ANAVEX2-73)及其在治疗阿尔海默氏病和其他由σ1受体调节的疾病中的用途
RS51790B (sr) Upotreba derivata benzo-kondenzovanih heterocikličkih sulfamida za lečenje manije i bipolarnog poremećaja
AU2002242296A1 (en) Carbamate compounds for use in preventing or treating psychotic disorders
US20090275597A1 (en) Methods of treating cns disorders
US20250302773A1 (en) Compositions comprising meai and n-acylethanolamines and uses thereof
RS50505B (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju anksioznih poremećaja
AU2016218950C1 (en) Analgesic formulation
KR20180103846A (ko) 항불안제 제조시 치환된 신남아미드 유도체의 적용
EP3302493B1 (en) Inhibitors of cystine-glutamate transporter for use in treating or preventing substance-related and addictive disorders
ZA200307469B (en) Carbamate compounds for use in preventing or treating psychotic disorders.
RS4604A (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neuropatskog bola u vezi sa klasterskim i migrenskim glavoboljama
Maan Comparison of Methamphetamine and MDMA Extended Access Self-administration: Acquisition, Maintenance, and Response patterns
RS4504A (sr) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju neuropatskog bola u vezi sa klasterskim i migrenskim glavoboljama
Rock Cannabidiol Indirectly Activates 5-HT1A Somatodendritic Autoreceptors to Attenuate Vomiting and Nausea
Al Mustafa et al. Assessment of Neuro-Behavioral Effects of Scopolamine in Male Mice
Kertész et al. P. 1. c. 044 Improvement of AMPA antagonist activity by methyl substitution on the aniline ring of 2, 3-benzodiazepine derivatives